Founded in Paris in 1920, Gide is a leading international law firm with 12 offices spread throughout the world.
Gide is physically present in six regions of the world, with 11 offices, enabling it to act on cases globally.
12 September 2023
Deals | France | FIN
Gide advised Inventiva, a French a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs on a parallel issuance of securities comprising (i) a capital increase reserved to specified categories of investors for an amount of €30.6 million and (ii) the issuance for €5.1 million of "royalty certificates", innovative sui generis debt instruments that represent the right of its holder to receive an amount based on a portion of the net sales of the product containing lanifibranor, the lead product candidate in development by Inventiva for the treatment of NASH.
The financing have been subscribed by existing shareholders and new investors and will allow the Company to pursue its Phase III clinical trial evaluating lanifibranor in the treatment of patients suffering from NASH.
Inventiva is a listed company on the regulated market of Euronext Paris and the Nasdaq Global Market.
Gide’s team comprised partner Arnaud Duhamel, counsel Aude-Laurène Dourdain, and associates Marie-Hélène Gryparis, Lauren Baker, Elise Raymond on the capital markets aspects, partner Alexandre Bochu on the tax aspects and partner Raphaëlle Dequiré-Portier on the intellectual property aspects.
